3,025 reports of this reaction
3.1% of all Abilify Maintena reports
#3 most reported adverse reaction
PRODUCT USE IN UNAPPROVED INDICATION is the #3 most commonly reported adverse reaction for Abilify Maintena, manufactured by Otsuka America Pharmaceutical, Inc.. There are 3,025 FDA adverse event reports linking Abilify Maintena to PRODUCT USE IN UNAPPROVED INDICATION. This represents approximately 3.1% of all 96,636 adverse event reports for this drug.
Patients taking Abilify Maintena who experience product use in unapproved indication should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRODUCT USE IN UNAPPROVED INDICATION is moderately reported among Abilify Maintena users, representing a notable but not dominant share of adverse events.
In addition to product use in unapproved indication, the following adverse reactions have been reported for Abilify Maintena:
The following drugs have also been linked to product use in unapproved indication in FDA adverse event reports:
PRODUCT USE IN UNAPPROVED INDICATION has been reported as an adverse event in 3,025 FDA reports for Abilify Maintena. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRODUCT USE IN UNAPPROVED INDICATION accounts for approximately 3.1% of all adverse event reports for Abilify Maintena, making it one of the most commonly reported side effect.
If you experience product use in unapproved indication while taking Abilify Maintena, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.